New antiviral therapies in the management of HCV infection

被引:22
作者
Farnik, Harald [1 ]
Zeuzem, Stefan [1 ]
机构
[1] Klinikum JW Goethe Univ, Med Klin 1, Frankfurt, Germany
关键词
HEPATITIS-C-VIRUS; TREATMENT-NAIVE PATIENTS; SUSTAINED VIROLOGICAL RESPONSE; NS3 PROTEASE INHIBITOR; PEGYLATED INTERFERON-ALPHA; GENOTYPE; POLYMERASE INHIBITOR; PLUS RIBAVIRIN; PEGINTERFERON ALPHA-2A; NS5A INHIBITOR;
D O I
10.3851/IMP2127
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Improved knowledge of the HCV life cycle and of structural features of HCV proteins have led to the discovery of numerous potential targets for antiviral therapy. Viral replication and polyprotein processing have been tagged as promising viral targets. Clathrin-mediated endocytosis, fusion of HCV with cellular membranes, translation of viral RNA, virus production and release as well as several host cell factors may provide alternative targets for future anti-HCV therapies. Several compounds are currently under investigation in clinical trials and showed high antiviral activity in patients with chronic hepatitis C. Recently, Phase III studies for two protease inhibitors, telaprevir and boceprevir, each given in combination with pegylated interferon (standard of care [SOC]), were completed. In HCV-genotype-1-infected patients, the addition of telaprevir or boceprevir to SOC increased sustained virological response rates from <50% to >70%. Nucleoside/nucleotide inhibitors of the HCV NS5B polymerase have shown antiviral activity against different HCV genotypes, and have a higher barrier to resistance than protease inhibitors. In addition, several allosteric binding sites have been identified for non-nucleoside inhibitors of the NS5B polymerase. Inhibitors of NS5A are potentially active against all HCV genotypes. Among the different host cell-targeting compounds, cyclophilin inhibitors have shown promising results. Future hope lies in the combination of direct-acting antiviral agents with the possibility of interferon-free treatment regimens.
引用
收藏
页码:771 / 783
页数:13
相关论文
共 88 条
[61]   FIRST SVR DATA WITH THE NUCLEOSIDE ANALOGUE POLYMERASE INHIBITOR MERICITABINE (RG7128) COMBINED WITH PEGINTERFERON/RIBAVIRIN IN TREATMENT-NAIVE HCV G1/4 PATIENTS: INTERIM ANALYSIS FROM THE JUMP-C TRIAL [J].
Pockros, P. ;
Jensen, D. ;
Tsai, N. ;
Taylor, R. M. ;
Ramji, A. ;
Cooper, C. ;
Dickson, R. ;
Tice, A. ;
Stancic, S. ;
Ipe, D. ;
Thommes, J. A. ;
Vierling, J. M. .
JOURNAL OF HEPATOLOGY, 2011, 54 :S538-S538
[62]   A PHASE 2, RANDOMIZED STUDY OF HCV-796 IN COMBINATION WITH PEGYLATED-INTERFERON (PEG) PLUS RIBAVIRIN (RBV) VERSUS PEG PLUS RBV IN HEPATITIS C VIRUS GENOTYPE-1 INFECTION [J].
Pockros, P. ;
Rodriguez-Torres, M. ;
Villano, S. ;
Maller, E. ;
Chojkier, M. .
JOURNAL OF HEPATOLOGY, 2009, 50 :S7-S8
[63]   R1626 plus peginterferon alfa-2a provides potent suppression of hepatitis C virus RNA and significant antiviral synergy in combination with ribavirin [J].
Pockros, Paul J. ;
Nelson, David ;
Godofsky, Eliot ;
Rodriguez-Torres, Maribel ;
Everson, Gregory T. ;
Fried, Michael W. ;
Ghalib, Reem ;
Harrison, Stephen ;
Nyberg, Lisa ;
Shiffman, Mitchell L. ;
Najera, Isabel ;
Chan, Anna ;
Hill, George .
HEPATOLOGY, 2008, 48 (02) :385-397
[64]   FIRST REPORT OF SVR12 FOR A NS5A REPLICATION COMPLEX INHIBITOR, BMS-790052 IN COMBINATION WITH PEG-IFNα-2A AND RBV: PHASE 2A TRIAL IN TREATMENT-NAIVE HCV-GENOTYPE-1 SUBJECTS [J].
Pol, S. ;
Ghalib, R. H. ;
Rustgi, V. K. ;
Martorell, C. ;
Everson, G. T. ;
Tatum, H. A. ;
Hezode, C. ;
Lim, J. K. ;
Bronowicki, J. -P. ;
Abrams, G. A. ;
Brau, N. ;
Morris, D. W. ;
Thuluvath, P. ;
Reindollar, R. ;
Yin, P. D. ;
Diva, U. ;
Hindes, R. ;
McPhee, F. ;
Gao, M. ;
Thiry, A. ;
Schnittman, S. ;
Hughes, E. A. .
JOURNAL OF HEPATOLOGY, 2011, 54 :S544-S545
[65]   ONCE-DAILY NS5A INHIBITOR (BMS-790052) PLUS PEGINTERFERON-ALPHA-2A AND RIBAVIRIN PRODUCES HIGH RATES OF EXTENDED RAPID VIROLOGIC RESPONSE IN TREATMENT-NAIVE HCV-GENOTYPE 1 SUBJECTS: PHASE 2A TRIAL [J].
Pol, S. ;
Everson, G. ;
Ghalib, R. ;
Rustgi, V. ;
Martorell, C. ;
Tatum, H. A. ;
Lim, J. ;
Hezode, C. ;
Diva, U. ;
Yin, P. D. ;
Hindes, R. .
JOURNAL OF HEPATOLOGY, 2010, 52 :S462-S462
[66]   Boceprevir for Untreated Chronic HCV Genotype 1 Infection [J].
Poordad, Fred ;
McCone, Jonathan, Jr. ;
Bacon, Bruce R. ;
Bruno, Savino ;
Manns, Michael P. ;
Sulkowski, Mark S. ;
Jacobson, Ira M. ;
Reddy, K. Rajender ;
Goodman, Zachary D. ;
Boparai, Navdeep ;
DiNubile, Mark J. ;
Sniukiene, Vilma ;
Brass, Clifford A. ;
Albrecht, Janice K. ;
Bronowicki, Jean-Pierre ;
Colombato, L. ;
Curciarello, J. ;
Silva, M. ;
Tanno, H. ;
Terg, R. ;
Adler, M. ;
Langlet, P. ;
Lasser, L. ;
Nevens, F. ;
Anderson, F. ;
Bailey, R. ;
Bilodeau, M. ;
Cooper, C. ;
Feinman, S. V. ;
Heathcote, J. ;
Levstik, M. ;
Ramji, A. ;
Sherman, M. ;
Shafran, S. ;
Yoshida, E. ;
Achim, A. ;
Ben Ali, S. ;
Bigard, M-A. ;
Bonny, C. ;
Bourliere, M. ;
Boyer-Darrigrand, N. ;
Bronowicki, J-P. ;
Canva, V. ;
Couzigou, P. ;
De Ledinghen, V. ;
Guyader, D. ;
Hezode, C. ;
Larrey, D. ;
Latournerie, M. ;
Marcellin, P. .
NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (13) :1195-1206
[67]   Virologic Response Rates of Weight-Based Taribavirin Versus Ribavirin in Treatment-Naive Patients with Genotype 1 Chronic Hepatitis C [J].
Poordad, Fred ;
Lawitz, Eric ;
Shiffman, Mitchell L. ;
Hassanein, Tarek ;
Muir, Andrew J. ;
Bacon, Bruce R. ;
Heise, Jamie ;
Halliman, Deanine ;
Chun, Eric ;
Hammond, Janet .
HEPATOLOGY, 2010, 52 (04) :1208-1215
[68]   Viral hepatitis C [J].
Poynard, T ;
Yuen, MF ;
Ratziu, V ;
Lai, CL .
LANCET, 2003, 362 (9401) :2095-2100
[69]   Rapid decline of viral RNA in hepatitis C patients treated with VX-950: A phase Ib, placebo-controlled, randomized study [J].
Reesink, Hendrik W. ;
Zeuzem, Stefan ;
Weegink, Christine J. ;
Forestier, Nicole ;
Van Vliet, Andre ;
Van De Wetering De Rooij, Jeroen ;
McNair, Lindsay ;
Purdy, Susan ;
Kauffman, Robert ;
Alam, John ;
Jansen, Peter L. M. .
GASTROENTEROLOGY, 2006, 131 (04) :997-1002
[70]   Robust antiviral activity of R1626, a novel nucleoside analog: A randomized, placebo-controlled study in patients with chronic hepatitis C [J].
Roberts, Stuart K. ;
Cooksley, Graham ;
Dore, Gregory J. ;
Robson, Richard ;
Shaw, David ;
Berns, Heather ;
Hill, George ;
Klumpp, Klaus ;
Najera, Isabel ;
Washington, Carla .
HEPATOLOGY, 2008, 48 (02) :398-406